







Newsletter #9

03 December 2021

Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration

Total number	of cases reporte	ed			88	
Countries that	assessed childr	ren. n				
Argentina	1	Mexico	2	Swed	en 1	
France	49	Poland	12	Turke	Turkey 1	
Greece	1	Portugal	2		United Kingdom 1	
India	4	Romania	3		, and the second	
Italy	4	Russia	6			
Children						
Girls / boys					37 / 50	
Age (mean ± SD)					12.3 ± 3.8 y	
Psoriasis befor						
Age of onset of psoriasis (mean ± SD)					7.0 ± 4.0 y	
Plaque psoriasis					57	
Nail psoriasis					40	
Psoriasis art	thritis				6	
COVID-19						
Confirmed / suspected					77 / 11	
N° of COVID-19 / child						
1					86	
2					1	
Symptoms, yes					59	
Hospitalization					5	
Long-Covid					2	
Since COVID-19 onset, the psoriasis has						
Improved					0	
Worsened, with same psoriasis phenotype					10	
Worsened, phenotype changed					1	
Remained s					64	
Psoriasis de					5	
No informat	tion				8	
Systemic medi	cation for psori	asis at time of onset	t of COVID-19			
Photothera				alimumab	10	
Methotrexa	ite 11		Eta	nercept	4	
Acitretin	4		Ust	ekinumab	11	
Cyclosporin	e 1		Risa	ankizumab	1	

You can include children with psoriasis and COVID-19 on:

 $https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfncx4ky8CEUILWa7veJmHb0FthGKuudaQD\\ wbCfNQ/viewform?vc=0\&c=0\&w=1\&flr=0$

Apremilast

1